vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $1.2M, roughly 1.2× CALLAN JMB INC.). CALLAN JMB INC. runs the higher net margin — -223.8% vs -417.9%, a 194.2% gap on every dollar of revenue.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
CJMB vs PSTV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.4M |
| Net Profit | $-2.6M | $-5.7M |
| Gross Margin | 30.3% | — |
| Operating Margin | -216.6% | -420.0% |
| Net Margin | -223.8% | -417.9% |
| Revenue YoY | — | -3.2% |
| Net Profit YoY | — | -46.4% |
| EPS (diluted) | $-0.58 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.4M | ||
| Q3 25 | $1.4M | $1.4M | ||
| Q2 25 | $1.7M | $1.4M | ||
| Q1 25 | $1.4M | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-2.6M | $-5.7M | ||
| Q3 25 | $-2.7M | $-4.4M | ||
| Q2 25 | $-1.4M | $5.2M | ||
| Q1 25 | $-1.2M | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | — | $-3.3M |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -216.6% | -420.0% | ||
| Q3 25 | -129.9% | -320.8% | ||
| Q2 25 | -84.2% | -110.6% | ||
| Q1 25 | -85.4% | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | — | -260.9% | ||
| Q2 24 | — | -289.1% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | -223.8% | -417.9% | ||
| Q3 25 | -188.8% | -316.6% | ||
| Q2 25 | -83.9% | 370.6% | ||
| Q1 25 | -85.6% | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | — | -197.4% | ||
| Q2 24 | — | -229.9% | ||
| Q1 24 | — | -194.5% |
| Q4 25 | $-0.58 | $0.95 | ||
| Q3 25 | $-0.61 | $-0.04 | ||
| Q2 25 | $-0.31 | $-0.01 | ||
| Q1 25 | $-0.32 | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | — | $-0.71 | ||
| Q1 24 | — | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $4.0M |
| Total Assets | $5.8M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $8.6M | ||
| Q3 25 | $2.8M | $16.6M | ||
| Q2 25 | $4.2M | $6.9M | ||
| Q1 25 | $5.2M | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | $2.3M | $4.0M | ||
| Q3 25 | $4.2M | $5.1M | ||
| Q2 25 | $5.8M | $3.0M | ||
| Q1 25 | $6.8M | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | — | $-7.6M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | $5.8M | $16.3M | ||
| Q3 25 | $7.7M | $18.7M | ||
| Q2 25 | $9.0M | $10.3M | ||
| Q1 25 | $8.5M | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $11.2M | ||
| Q1 24 | — | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | $-6.3M | ||
| Q3 25 | $-1.8M | $-2.5M | ||
| Q2 25 | $-563.3K | $-5.8M | ||
| Q1 25 | $-1.6M | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $-1.9M | $-2.6M | ||
| Q2 25 | $-995.8K | $-5.8M | ||
| Q1 25 | $-1.6M | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | -133.5% | -184.3% | ||
| Q2 25 | -59.8% | -417.6% | ||
| Q1 25 | -108.8% | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | 0.0% | 2.2% | ||
| Q3 25 | 11.7% | 1.9% | ||
| Q2 25 | 26.0% | 0.5% | ||
| Q1 25 | 1.0% | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
PSTV
Segment breakdown not available.
